HSGX - ヒストジェニックス (Histogenics Corporation) ヒストジェニックス

 HSGXのチャート


 HSGXの企業情報

symbol HSGx
会社名 Histogenics Corp (ヒストジェニックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Industrial Specialties  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company''s product candidate NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient''s own cartilage cells through a series of tissue engineering processes. The patient''s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient the cell- and scaffold construct undergoes a bioengineering process in the Company''s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.   ヒストジェニックスは、米国の再生医療企業。市場の筋骨格分野向けの製品の開発および商業化に従事。細胞療法と組織工学技術を組み合わせ、軟骨由来の特定の痛みと不動状態にある患者に焦点を当てた組織の修復・再生のための製品を開発する。膝軟骨損傷の治療用NeoCartのほか、軟骨損傷を防止する技術と製品の開発手掛ける。   Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
本社所在地 830 Winter Street 3rd Floor Waltham MA 02451 USA
代表者氏名 Garheng Kong Garheng Kong
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-457-7900
設立年月日 36678
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 45人
url www.histogenics.com
nasdaq_url https://www.nasdaq.com/symbol/hsgx
adr_tso
EBITDA EBITDA(百万ドル) -23.97800
終値(lastsale) 0.584
時価総額(marketcap) 16814238.336
時価総額 時価総額(百万ドル) 39.87468
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 31.10268
当期純利益 当期純利益(百万ドル) -27.48600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Histogenics Corp revenues was not reported. Net loss increased 37% to $18.6M. Higher net loss reflects Change in fair value of warrant liabilit increase from $404K to $5.3M (expense) Interest Income (expense) net decrease of 8% to $69K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.62 to -$0.67.

 HSGXのテクニカル分析


 HSGXのニュース

   Ocular Biotechs Histogenics (NASDAQ:HSGX), Ocugen Announce Stock-For-Stock Merger  2019/04/08 12:48:00 Benzinga
​ Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming …
   Histogenics up 170% premarket on Ocugen merger  2019/04/08 12:19:02 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Ocular Biotechs Histogenics (NASDAQ:HSGX), Ocugen Announce Stock-For-Stock Merger  2019/04/08 12:48:00 Benzinga
​ Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming …
   Histogenics up 170% premarket on Ocugen merger  2019/04/08 12:19:02 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Ocular Biotechs Histogenics (NASDAQ:HSGX), Ocugen Announce Stock-For-Stock Merger  2019/04/08 12:48:00 Benzinga
​ Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming …
   Histogenics up 170% premarket on Ocugen merger  2019/04/08 12:19:02 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha

 関連キーワード  (医薬品 米国株 ヒストジェニックス HSGX Histogenics Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)